Bora Pharmaceuticals and GSK announced today that they entered into a $250 million agreement to renew a five-year manufacturing partnership. In 2020, Bora purchased a facility in Mississauga, Ontario, from GSK. Now, they say the renewed collaboration reinforces their long-standing relationship and expands their partnership. It also provides GSK access to multiple sites within the…
Bora Pharmaceuticals completes buy of Emergent BioSolutions’ Baltimore manufacturing plant
Emergent BioSolutions announced that it completed the sale of a drug product facility in Maryland to an affiliate of Bora Pharmaceuticals. The Gaithersburg, Maryland-based Narcan maker announced the sale of the facility to Bora in June. Bora paid approximately $30 million at closing for the facility, located in Baltimore-Camden. The site made up part of…
Emergent BioSolutions sells Baltimore manufacturing plant to Bora for $30M
Emergent BioSolutions this week announced it entered into a definitive agreement to sell its Baltimore-Camden drug product facility. The Gaithersburg, Maryland-based company will sell the facility to an affiliate of Bora Pharmaceuticals for approximately $30 million. Emergent’s Camden site is part of the company’s Contract Development and Manufacturing Organization (CDMO) and has clinical and commercial…
Bora Pharmaceuticals is buying generics maker Upsher-Smith
Bora Pharmaceuticals announced that its board approved the acquisition of Upsher-Smith Laboratories for up to $210 million. Minnesota-based Upsher-Smith features a diversified portfolio of 48 generic products. It has manufacturing facilities in Plymouth and Maple Grove, Minnesota. Taipei, Taiwan-based Bora called the company a reliable partner with solid manufacturing capabilities, a robust distribution network and…